LYRA (Lyra Therapeutics, Inc.) חוב לטווח קצר להון
This visual market valuation helps analyze the resilience of Lyra Therapeutics, Inc. (LYRA), whose competitive moat is based on nasal implant patents and lobbyist support under strict FDA oversight. The indicator stands at 0.00. Lyra Therapeutics, Inc. (LYRA) is implementing eco-friendly synthesis and zero-waste chemical disposal. The business relies on an open niche for non-surgical rhinosinusitis treatment, ensuring stable demand from physicians.
פילוחים אנליטיים של חברת Lyra Therapeutics, Inc.
This ratio determines the share of short-term liabilities within the equity structure, reflecting the issuer's level of dependence on operational debt financing. By analyzing the trend of short-term debt to equity, an investor can assess the financial stability of Lyra Therapeutics, Inc. (LYRA) while scaling its drug delivery platform and preparing for the mass market launch of ENT products.